Clinical Trial Update: Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an early-phase study evaluating the safety and efficacy of combining Fruquintinib and Pirfenidone with an anti-PD-1 antibod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anti-PD-1 antibody
• Fruquintinib (fruquintinib)
• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma, To Evaluate Whether Pirfenidone Can Reshape the Tumor Microenvironment in Colorectal Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING